(a) An advertisement of a drug or device is false if the advertisement represents that the drug or device affects:
(1) infectious and parasitic diseases;
(2) neoplasms;
(3) endocrine, nutritional, and metabolic diseases and immunity disorders;
(4) diseases of blood and blood-forming organs;
(5) mental disorders;
(6) diseases of the nervous system and sense organs;
(7) diseases of the circulatory system;
(8) diseases of the respiratory system;
(9) diseases of the digestive system;
(10) diseases of the genitourinary system;
(11) complications of pregnancy, childbirth, and the puerperium;
(12) diseases of the skin and subcutaneous tissue;
(13) diseases of the musculoskeletal system and connective tissue;
(14) congenital anomalies;
(15) certain conditions originating in the perinatal period;
(16) symptoms, signs, and ill-defined conditions; or
(17) injury and poisoning.
(b) Subsection (a) does not apply to an advertisement of a drug or device if the advertisement does not violate Section 431.182 and is disseminated:
(1) to the public for self-medication and is consistent with the labeling claims permitted by the federal Food and Drug Administration;
(2) only to members of the medical, dental, and veterinary professions and appears only in the scientific periodicals of those professions; or
(3) only for the purpose of public health education by a person not commercially interested, directly or indirectly, in the sale of the drug or device.
(c) The executive commissioner by rule shall authorize the advertisement of a drug having a curative or therapeutic effect for a disease listed under Subsection (a) if the executive commissioner determines that an advance in medical science has made any type of self-medication safe for the disease. The executive commissioner may impose conditions and restrictions on the advertisement of the drug necessary in the interest of public health.
(d) This section does not indicate that self-medication for a disease other than a disease listed under Subsection (a) is safe or effective.